Back to Biomarkers List
Associated Genetic Biomarkers
PROS1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains PROS1 status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with PROS1 status in the inclusion eligibility criteria most commonly target adenocarcinoma of the gastroesophageal junction and gastric adenocarcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is PROS1 Expression .
Docetaxel and selumetinib are the most frequent therapies in trials with PROS1 as an inclusion criteria .
Significance of PROS1 in Diseases
Adenocarcinoma Of The Gastroesophageal Junction +
PROS1 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains PROS1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (0 open) .
Gastric Adenocarcinoma +
PROS1 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PROS1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) .
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.